A case of Rowell syndrome with excellent improvement following anifrolumab

[1]  G. Foulke,et al.  Anifrolumab for treatment of refractory cutaneous lupus erythematosus , 2022, Clinical and experimental dermatology.

[2]  E. Deeks.  Anifrolumab: First Approval , 2021, Drugs.

[3]  P. Padhan,et al.  Rowell's Syndrome: A Case Report and Literature Overview , 2021, Indian dermatology online journal.

[4]  E. Morand,et al.  Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus , 2021, Lupus.

[5]  A. Crowson,et al.  Targetoid lesions in a patient with systemic lupus erythematosus. , 2021, Dermatology online journal.

[6]  Yoshiya Tanaka.  State‐of‐the‐art treatment of systemic lupus erythematosus , 2020, International journal of rheumatic diseases.

[7]  G. Fabbrocini,et al.  Rowell Syndrome: A Diagnostic Challenge. , 2019, The Journal of clinical and aesthetic dermatology.

[8]  I. Bruce,et al.  Trial of Anifrolumab in Active Systemic Lupus Erythematosus. , 2019, The New England journal of medicine.

[9]  V. Werth,et al.  Cutaneous lupus erythematosus: diagnosis and treatment. , 2013, Best practice & research. Clinical rheumatology.

[10]  A. Dogra,et al.  Rowell's Syndrome. , 2000, Indian journal of dermatology, venereology and leprology.